Free Trial
NASDAQ:TERN

Terns Pharmaceuticals Q4 2024 Earnings Report

Terns Pharmaceuticals logo
$3.50 -0.06 (-1.69%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$3.43 -0.07 (-2.11%)
As of 05/2/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Terns Pharmaceuticals EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.30
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Terns Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Terns Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 20, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Terns Pharmaceuticals' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Terns Pharmaceuticals Earnings Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Does Terns Pharmaceuticals Have A Long Cash Runway?
Terns Pharmaceuticals management to meet with Oppenheimer
See More Terns Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Terns Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Terns Pharmaceuticals and other key companies, straight to your email.

About Terns Pharmaceuticals

Terns Pharmaceuticals (NASDAQ:TERN), a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

View Terns Pharmaceuticals Profile

More Earnings Resources from MarketBeat